Blog
RSS FeedPosted by Michael Wonder on 24 Oct 2023
Abiraterone: thousands of men miss out on life-extending prostate cancer drug
24 October 2023 - Thousands of patients in England and Northern Ireland are missing out on a life-extending prostate cancer ...
Posted by Michael Wonder on 21 Oct 2023
Brukinsa receives positive recommendation from NICE in the UK for adult patients with chronic lymphocytic leukaemia
20 October 2023 - BeiGene today announced that NICE of the United Kingdom has issued a final draft guidance recommending ...
Posted by Michael Wonder on 19 Oct 2023
Tabelecleucel for the treatment of patients with a post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus
19 October 2023 - NICE is unable to make a recommendation on the use of tabelecleucel (Ebvallo) for the treatment of ...
Posted by Michael Wonder on 19 Oct 2023
Daridorexant hydrochloride for the treatment of patients with long-term insomnia
18 October 2023 - NICE has published final evidence based recommendations on the use of daridorexant hydrochloride (Quviviq) for the ...
Posted by Michael Wonder on 19 Oct 2023
Ruxolitinib phosphate for the treatment of patients with polycythaemia vera
18 October 2023 - NICE has published final evidence based recommendations on the use of ruxolitinib phosphate (Jakavi) for the ...
Posted by Michael Wonder on 19 Oct 2023
Tofacitinib citrate for the treatment of patients with active ankylosing spondylitis
18 October 2023 - NICE has published final evidence-based recommendations on the use of tofacitinib citrate (Xeljanz) for the treatment ...
Posted by Michael Wonder on 18 Oct 2023
Rimegepant sulphate for the treatment of patients with acute migraine
18 October 2023 - NICE has published final evidence based recommendations on the use of rimegepant sulphate (Vydura) for the ...
Posted by Michael Wonder on 17 Oct 2023
First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK
17 October 2023 - More than 700 people set to benefit from new treatment option for advanced lymphoma. ...
Posted by Michael Wonder on 17 Oct 2023
Glofitamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
17 October 2023 - NICE has published final evidence based recommendations on the use of glofitamab (Columvi) for the treatment ...
Posted by Michael Wonder on 16 Oct 2023
UK faces £50 billion economic hit due to spiralling medicines levy
12 October 2023 - A year on from the publication of analysis, which found that excessive double digit UK rebates ...
Posted by Michael Wonder on 12 Oct 2023
Life sciences leaders unite to condemn radical plans to rewrite medicines scheme
9 October 2023 - Over twenty industry leaders from companies supplying the NHS with essential medicines warn that radical plans to ...
Posted by Michael Wonder on 11 Oct 2023
Bimekizumab for the treatment of patients with axial spondyloarthritis
11 October 2023 - NICE has published final evidence based recommendations on the use of bimekizumab (Bimzelx) for the treatment ...
Posted by Michael Wonder on 09 Oct 2023
Ravulizumab for the treatment of adults with generalised myasthenia gravis
4 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using ravulizumab ...
Posted by Michael Wonder on 09 Oct 2023
The evolving nature of health technology assessment: a critical appraisal of NICE’s new methods manual
6 October 2023 - NICE recently completed a review of its methods for health technology assessment, involving a 2 stage ...
Posted by Michael Wonder on 08 Oct 2023
Belumosudil mesylate for the treatment of patients with chronic graft versus host disease after two or more lines of systemic therapy
4 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...